VIM Trial results favor PDT for small, subfoveal minimally classic,AMD-related CNV

Verteporfin (Visudyne) photodynamic therapy (PDT) using either a reducedor standard light fluence rate appears to be beneficial for patients withrelatively small, subfoveal minimally classic CNV associated with age-relatedmacular degeneration (AMD), said Philip J. Rosenfeld, MD.